Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec;74(6):932-9.
doi: 10.1111/j.1365-2125.2012.04280.x.

The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics

J G Coen van Hasselt  1 , Marilee A Andrew, Mary F Hebert, Joel Tarning, Paolo Vicini, Donald R Mattison
Affiliations
Review

The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics

J G Coen van Hasselt et al. Br J Clin Pharmacol. 2012 Dec.

Abstract

Physiological changes during pregnancy may alter drug pharmacokinetics. Therefore, mechanistic understanding of these changes and, ultimately, clinical studies in pregnant women are necessary to determine if and how dosing regimens should be adjusted. Because of the typically limited number of patients who can be recruited in this patient group, efficient design and analysis of these studies is of special relevance. This paper is a summary of a conference session organized at the American Conference of Pharmacometrics in April 2011, around the topic of applying pharmacometric methodology to this important problem. The discussion included both design and analysis of clinical studies during pregnancy and in silico predictions. An overview of different pharmacometric methods relevant to this subject was given. The impact of pharmacometrics was illustrated using a range of case examples of studies around pregnancy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of pharmacometrics approaches in design and analysis of clinical studies in pregnant women
See this image and copyright information in PMC

References

    1. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191:398–407. - PubMed
    1. Saunders EJ, Saunders JA. Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int. 1990;11:423–32. - PubMed
    1. McCullough LB, Coverdale JH, Chervenak FA. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. Am J Obstet Gynecol. 2005;193:901–7. - PubMed
    1. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989–1008. - PubMed
    1. Feghali MN, Mattison DR. Clinical therapeutics in pregnancy. J Biomed Biotechnol. 2011;2011:783528. - PMC - PubMed

Publication types